Crinetics Pharmaceuticals Inc Dossier - Source-backed chat

Crinetics Pharmaceuticals Inc

CRNXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.41

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $84.95Price as of 31 Aug 2026

Data confidenceNot applicable

Market Cap $9B

Enterprise Value $9B

Shares Outstanding 105.4M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Crinetics Pharmaceuticals is successfully transitioning from a clinical-stage R&D platform to a commercial-stage endocrinology powerhouse. The launch of PALSONIFY (paltusotine), the first once-daily oral treatment approved for acromegaly, is showing strong early commercial traction with $10.3 million in net product revenue in Q1 2026. This commercial launch is backed by a robust balance sheet of $1.3 billion in cash and investments, providing a runway into 2030. Furthermore, the company's pipeline is highly promising, led by atumelnant, which is advancing into late-stage development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome following strong Phase 2 data presented at ENDO 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$85.00

Mean target$85.50

High · most bullish analyst$90.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$85.00

PALSONIFY commercial uptake slows due to payer pushback or rigid preference for established injectable therapies. High R&D and SG&A cash burn (guided at $600M-$650M GAAP for 2026) depletes cash reserves faster than anticipated, forcing highly dilutive equity raises, while clinical trials for atumelnant face enrollment delays.

Base CaseCentral scenario

$85.50

Matches the consensus mean

PALSONIFY continues its steady commercial ramp, meeting consensus revenue expectations while maintaining high reimbursement rates (~70%+). Atumelnant successfully advances through its Phase 3 CALM-CAH and Phase 2/3 EQUILIBRIUM trials on schedule, and the company's cash runway remains sufficient to fund operations without immediate dilutive financing.

Bull CaseUpside scenario

$90.00

PALSONIFY experiences rapid market adoption, capturing a significant share of the acromegaly market from injectable somatostatin receptor ligands (SRLs) due to its oral convenience and strong clinical profile. Concurrently, atumelnant delivers outstanding Phase 3 results in CAH, accelerating its path to regulatory approval and establishing a multi-billion dollar endocrine franchise.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage with PALSONIFY as the first once-daily oral therapy approved for acromegaly, offering a highly attractive alternative to painful monthly injections.
Strong early commercial execution with $10.3 million in product sales in Q1 2026, supported by growing prescriber adoption and ~70% reimbursement coverage.
Robust balance sheet with $1.3 billion in cash, cash equivalents, and investments as of March 31, 2026, extending the operational runway into 2030.
Deep and highly promising pipeline led by atumelnant, which demonstrated a 67% mean reduction in androstenedione levels in CAH patients during Phase 2 trials.

Key Investment Risks

High operational cash burn, with 2026 GAAP operating expenses guided at $600 million to $650 million, creating long-term dilution risk if commercial revenues do not scale rapidly.
Payer and reimbursement hurdles that could restrict patient access or slow down the commercial adoption of PALSONIFY.
Clinical and regulatory risks associated with late-stage pipeline candidates, particularly atumelnant in CAH and Cushing's syndrome.

Thesis Invalidation Triggers

A significant drop in PALSONIFY quarterly sales or a flatlining of new patient enrollment forms.
Failure of atumelnant to meet primary endpoints in its upcoming Phase 3 clinical trials.
Unexpected safety signals or regulatory setbacks for PALSONIFY in international markets (e.g., Europe, Japan, or Brazil).

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.